Metriopharm
  • en
  • de
MetrioPharm AG
  • Home
  • About us
    • Management and Board
    • Scientific Advisory Board
    • Senior Advisors
  • Technology
    • MP1000 Platform
    • Mode of Action
    • Scientific Publications
  • Pipeline
    • Overview
    • Clinical Trials
    • Patent Protection
  • Investors
    • IR-News
    • Share Information
    • Financial Reports and Downloads
    • Annual General Meeting
  • Press
    • Press Releases
    • Corporate Calendar
  • Contact
    • Contact form
    • Privacy policy
    • Imprint
  • Blog
  • en
  • de
  1. Home
  2. About us
  3. Sitemap

Sitemap

Get a quick overview:
We provide you a sitemap, which shows the structure of our website in a simple form.

 
  • Home
  • About us
    • Management and Board
    • Scientific Advisory Board
    • Senior Advisors
  • Technology
    • MP1000 Platform
    • Mode of Action
    • Scientific Publications
  • Pipeline
    • Overview
    • Clinical Trials
    • Patent Protection
  • Investors
    • IR-News
    • Share Information
    • Financial Reports and Downloads
    • Annual General Meeting
  • Press
    • Press Releases
    • Corporate Calendar
  • Contact
    • Contact form
    • Privacy policy
    • Imprint
  • Blog
 

News

Last Patient Out: MetrioPharm Completes Clinical Phase II Trial in COVID-19 - 2022-Jul-29

The objective of the study is to determine whether treatment with MetrioPharm’s lead compound MP1032 can slow the spread of the virus and alleviate COVID-19 symptoms in recently hospitalized patients.In preclinical trials the compound had shown both antiviral and anti-inflammatory properties.

» more

Investor Relations

Investor Relations News QII 2022 - 2022-Jun-30

16th Annual General Meeting of MetrioPharm AG, Bio-Europe Spring in Basel, BIO International Convention in San Diego, Company Calendar, London-Paris in 24 hours, MetrioPharm AG informs

» more

Blog

Read our latest blog post: - 2021-May-12

Phase II Clinical Trial in COVID-19

» more

Navigation

  • Home
  • About us
  • Technology
  • Pipeline
  • Investors
  • Press
  • Contact
  • Blog

Social

        

Newsletter

Subscribe to our press releases with the
MetrioPharm PR newsletter

Investors can subscribe to our quaterly corporate information with the
MetrioPharm IR newsletter

Switzerland (HQ)

MetrioPharm AG

Bleicherweg 10
8002 Zurich

Phone: +41 44 562 03 35

Germany (R&D)

MetrioPharm Deutschland GmbH

Am Borsigturm 100
13507 Berlin

Phone: +49 30 3384 395 02

  • © 2022 MetrioPharm AG
  • Imprint
  • Privacy policy
  • Sitemap